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1. Introduction 
With the increase in ways and means to improve health care there has been an increase in 
miseries of humanity a patient is often presented with several pathological situations that 
greatly necessitate the need for multiple drug administration and this in turn increases the 
chances of drug toxicity. Hence there is an immense need to explore such drug 
combinations that could be given safely to patients with multiple disorders.   
Multiple drug administration increases chances of drug interaction, altering the responses of 
drugs either increased or decreased pharmacological effects, or a new pharmacological 
response. Generally drug interactions should be avoided, due to the possibility of poor or 
unexpected outcomes and can be prevented with access to current, comprehensive and 
reliable information which may improve the safe and cost-effective patient care. Most 
countries face an augmented load of cardiovascular diseases (CVD) and epilepsy along with 
chronic non-communicable disorders such as diabetes mellitus. Hence it is essential to 
recognize the probable toxicities that might occur due to multiple drug administration. 
Occasionally these toxicities are predictable on the basis of known pharmacology of the 
drugs used, thus combinations require separate investigations with animal toxicity studies. 
1.1 Epilepsy 
Epilepsy is the leading neurological disorder in the world categorized by abnormal hyper 
excitability of the neurons causing seizures with or without loss of consciousness. These 
seizures are of short-term and an indication of unusual, extreme or synchronous neuronal 
activity in the brain (Fisher et al., 2005).  
Epilepsy represents the 3rd most common neurologic disorder in developed countries after 
stroke and dementias, encountered in elderly (Lim, 2004). The prevalence of epilepsy is around 
0.4 to 0.8 % (Brodie and Dichter, 1996) and its overall occurrence is around 50-70 cases per 100, 
000 in developed countries and 100 per 100, 000 in developing countries (Lim, 2004). Epilepsy 
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is a significant, but often underappreciated, health problem in Asia (Mac et al., 2007). It is 
estimated that approximately 50 million people worldwide have epilepsy (Kwan and Brodie, 
2000). This figure had recently reduced and it has been estimated that approximately 45 
million of population globally have epilepsy (French and Pedley, 2008). In Pakistan its 
predominance is approximately 1 % (Aziz et al., 1994 and 1997; Khatri et al., 2003). The utmost 
occurrence rate of 1.25% was found at the age group 20-29 years. The incidence rate gradually 
dropped, reaching the lowest of 0.49% in the age group of 50-59. Conversely the prevalence 
rate augmented again reaching to 1.1% at age > 60 years (Aziz et al., 1994).  
Etiology of epilepsy is age related, in children, approximately 20% are remote symptomatic, 
50% are cryptogenic while 30% are idiopathic. On the other hand, in elderly, approximately 
55% are remote symptomatic whereas 45% are idiopathic/ cryptogenic. In elderly causes 
and risk factors for seizures are significantly variable (LIM, 2004). The cumulative lifetime 
risks for epilepsy and unprovoked seizure in industrialized countries are 3.1% and 4.1%, 
respectively (McHugh and Norman, 2008). In most of the cases (62%) the reason is 
unidentified, stroke (9.0%), head trauma (9.0%), alcohol (6.0%), neurodegenerative disease 
(4.0%), static encephalopathy (3.5%), brain tumors (3.0%), and infection (2.0%) account for 
remaining cases. Although cerebrovascular reasons are more widespread in the old age, the 
reason is yet to be explored in 25% to 40% of patients who are 65 years of age or older 
(French and Pedley, 2008). Majority of the patients are well controlled on a single 
antiepileptic drug (Nadkarni et al., 2005). Since the early 1990s, a number of latest 
antiepileptic drugs have arrived in the market that proposed considerable benefits in terms 
of their favorable pharmacokinetics, enhanced tolerability and decrease probability for 
drug-drug interactions (Bialer and White, 2010). Every new drug offers a special profile of 
pharmacokinetics, undesirable effects, and mechanisms of action, making best utilization of 
these agents even more difficult (LaRoche and Helmers, 2004). Seizures can be managed in 
patients with epilepsy by means of conventional antiepileptic drugs, but regardless of 
optimal therapy 25% to 30% of patients continue to have seizures and others have 
undesirable side effects. Hence there is a need for additional drugs as well as new 
approaches for preventing epilepsy (Dichter and Brodie, 1996; Bialer and White, 2010).  
1.2 Hypertension 
Hypertension is a widespread human disease that badly affects approximately 1 billion 
people globally (Varon and Marik, 2003; Dickson and Sigmond, 2006; Chobanian, 2008). 
Unfortunately, regardless of current progresses in understanding and treating hypertension, 
its occurrence keeps on increasing. Worldwide 26% of the adult population suffers from 
hypertension (Dickson and Sigmond, 2006) and its occurrence is projected to boost up to 
60% by 2025, when a total of 1.56 billion people may be exaggerated. Pakistan ranks at 
number sixth in terms of its population (165million in 2007) which is constantly increasing at 
a rate about 1.83% per year, national heath surveys reveals that 33% of Pakistan’s 
population beyond the age of 45 has hypertension (Wasay and Jabbar, 2009). Hypertension 
is the foremost threat for cardiovascular disease (Lardinois, 1995; Peralta et al., 2007; 
Chobanian, 2008) responsible for one half of the coronary heart disease and about two third 
of the cerebrovascular disease load (Cutler et al., 2008) and is accountable for the most of 
deaths globally (Adrogue and Madias, 2007), even moderate increase in arterial blood 
pressure results in reduced life span.  
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1.3 Diabetes 
Diabetes mellitus and hypertension are widespread that exist together at a larger rate than 
the individual one (Sowers and Zemel, 1990; Epstein and Sowers, 1992; Tenenbaum et al., 
1999; Zanella et al., 2001). The occurrence of hypertension in the diabetic individual 
noticeably enhances the threat and hastens the course of cardiac disease, peripheral vascular 
disease, stroke, retinopathy, and nephropathy (Epstein and Sowers, 1992; Zanella et al., 
2001). The occurrence of simultaneous hypertension and diabetes appears to be growing in 
developed nations because populations are aging and both hypertension and non-insulin 
dependent diabetes mellitus occurrence increases as the age progresses (Sowers and Epstein, 
1995). People with diabetes faces two to four times augmented risk of CVD in contrast to the 
general population, simultaneous hypertension triples the already high risk of coronary 
artery disease, doubles total mortality and stroke risk, and may be accountable for up to 75% 
of all CVD  in people with diabetes (Stults and Jones, 2006). 
Rates of diabetes are increasing around the world (Kassab et al., 2001) which now becomes 
one of the major public health challenges for the 21st century. The increase occurrence in 
diabetes is because of aging population, obesity and stressing life style. Poverty has been 
under recognized as a contributor to prevalence of diabetes but it is strongly associated with 
the unhealthy alimentary habits (Krier et al., 1999; Riste et al., 2001). The incidence of 
diabetes get higher in the last decade because of factors that are strongly related to the life 
style as is inactivity and population aging (Muchmore et al., 1994; Keen, 1998). Studies show 
that type 2 diabetes affects 3% to 5% of the population in some countries and type 1 moves 
towards the younger ages (Dixon, 2002; Petkova et al., 2006). 
The increase rate of diabetes will be noticeably higher in developing countries, between 1995 
and 2025, the number of persons with diabetes is predictable to enhance by 170% in the 
developing world, in contrast with 42% in developed nations. Hence, by the year 2025 above 
75% of the people with diabetes will exist in developing countries (Nicolucci et al., 2006). A 
national health survey of Pakistan reveals that 25% of patients above 45 years have diabetes 
mellitus and Pakistan ranks number six globally in terms of prevalence of diabetes. It was 
projected that in 2000 there were 5.2 million diabetic patients and this will increase to 13.9 
million by 2020, leading Pakistan to 4th most populous country for diabetes mellitus (Wasay 
and Jabbar, 2009). However a survey conducted in 2010 by Hayat and Shaikh reveals that 
Pakistan ranks number seven on diabetes prevalence and figures show that about 6.9 
million people have diabetes. The International Diabetes Federation predicts that this 
number will rise to 11.5 million by 2025 if effective procedures are not taken to control the 
disease (Jawad, 2003). 
The occurrence of diabetes is continually growing and rising at a distressing rate, and it is 
projected that, unless successful prevention and control measures are put into practice, this 
disease will soon involve 300 million persons worldwide (Sowers, 2004). Globally more than 
170 million people have diabetes, and this figure is expected to be more than double by the 
year 2030, if existing trends continue (Boden and Taggart, 2009, Hoque et al., 2009).  
1.4 Arrhythmia 
Hypertension is usually linked with arrhythmias in patients with and without simultaneous 
CVD. There are studies which show the possible links between hypertension and atrial and 
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ventricular arrhythmias, though the principal pathophysiological mechanism remains 
unclear (Yiu and Tse, 2008). The prevalence and risk factors for arrhythmias vary among 
men and women (Wolbrette et al., 2002). The most prevalent arrhythmia seen in clinical 
practice is atrial fibrillation which currently influences more than 2 million Americans, with 
an expected rise to 10 million by the year 2050 (Zimetbaum, 2007). 
A patient is often presented with several other pathological states along with epilepsy; such 
as hypertension, arrhythmias, and diabetes, therefore it is essential to discover the drug-
drug interaction upon simultaneous use of anti-epileptic with antihypertensive, 
antiarrhythmic and antidiabetic. A well reported example is the increase in serum phenytoin 
levels when used concomitantly with amiodarone and therefore resulting in phenytoin 
toxicity (Lesko, 1989; Nolan et al., 1990) thus there is an massive need to assess the toxicities 
of multiple drug administration and to explore relatively safe combination for individuals 
with multiple disorders, not to predict but rather to warn the users and prescribers, of the 
possible dangers, to discourage the use of combination which have high cumulative 
toxicities in animals and to suggest more useful combination in countries where drug 
regulatory control is very poor.  
2. Biochemical testing and histopathological examination of liver toxicities 
Serum biochemical parameters can provide important and useful information in assessing 
not only the extent and severity of liver damage, but also the type of liver damage (Ramaiah, 
2007). Histopathological assessments also take part in the diagnosis of liver disease; 
moreover evaluation of morphological changes may provide additional information that 
may be useful for clinical management for example, grading of inflammatory activity and 
staging of fibrosis in chronic viral hepatitis, and the distinction between simple steatosis and 
steatohepatitis in alcoholic and non-alcoholic fatty liver disease (Hubscher, 2006). 
Liver function tests (LFT) are helpful screening tools to detect hepatic dysfunction (Kim, 
2008; Thapa and Walia, 2007; Astegiano et al., 2004). Since liver performs a variety of 
functions, no single test is sufficient enough to provide complete estimate of liver functions 
(Kim, 2008; Astegiano et al., 2004).  
Table 1A and 1B reveals the comparison of γ–glutamyl transferase (γ-GT), alkaline 
phosphatase (ALP), alanine transaminases (ALT), total bilirubin (TBR) and direct bilirubin 
(DBR) levels between control animals and animals kept on individual drugs and their 
combinations for a period of 60 days and then after drug free interval of 15 days in normal 
therapeutic doses. The administration of amiodarone (4.285 mg/kg) in rabbits shows highly 
significant elevation in the levels of serum γ–GT, ALP, ALT and DBR (Feroz et al., 2011a). 
There are studies in which long-term administration of amiodarone was associated with fatal 
hepatotoxicity (Richer and Robert, 1995; Usdin et al., 1996; Mendez et al., 1999) although most 
hepatic adverse effects were transient and reversible; however deaths have also been reported 
from amiodarone-induced hepatotoxicity (Richer and Robert, 1995). Microscopic examination 
of the hepatic tissue has shown mild diffuse cellular swelling in hepatocytes (Fig 1B). 
Moreover the administration of losartan potassium (0.892 mg/kg) and verapamil (1.714 
mg/kg) revealed highly significant elevation in serum ALP, elevations in serum ALP initiate 
predominantly from liver and bone (Renner and Dallenbach, 1992). There was also a 
significant elevation in TBR in animals kept on verapamil alone (Feroz et al., 2011a). However 
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no significant changes have been found in animals kept on glibenclamide (0.125 mg/kg), 
oxcarbazepine (18.5 mg/kg) and captopril (0.512 mg/Kg) alone. 
Data from animal’s studies also shows that the administration of amiodarone-glibenclamide- 
losartanpotassium- oxcarbazepine (AGLO) combination causes highly significant elevation in 
serum ALP. The transaminases, ALP and γ -GT are most widely used as indicators of 
hepatobiliary disease (Renner and Dallenbach, 1992). Increase in ALP might be due to 
cholestasis (Giannini et al., 2005) or it may also suggest a biliary tract disorder (Herlong, 1994). 
This explains that rise in ALP might be due to chloestatic diseases or partial obstruction of bile 
ducts or primary biliary cirrhosis (Pratt and Kaplan, 2000). Microscopic examination of hepatic 
tissue has shown moderate portal inflammation (Fig 1C). There was also a significant 
decreased in TBR in animals kept on AGLO combination (Feroz et al., 2011a). 
The administration of amiodarone-glibenclamide-verapamil-oxcarbazepine (AGVO) 
combination in animals shows highly significant elevation in γ -GT. Its level is elevated in a 
number of pathological conditions such as pancreatic disease, myocardial infarction, renal 
failure, chronic obstructive pulmonary disease, diabetes, and alcoholism. Measurement of 
serum γ -GT offers the presence or absence of hepatobiliary disease. Microscopic 
examination of hepatic tissue has shown congestion and mild mononuclear inflammatory 
infiltrate (Fig 1D). There was also a significant decreased in TBR in animals kept on AGVO 
combination (Feroz et al., 2011a). There has been a highly significant and significant 
decreased in ALT and TBR in animals kept on amiodarone-glibenclamide-captopril-
oxcarbazepine (AGCO) combination (Feroz et al., 2011a). Aminotransferase levels are 
sensitive indicators of liver-cell injury and are useful in identifying the hepatocellular 
disease (Pratt and Kaplan, 2000). Abnormal AST and ALT point to a hepatocyte disorder 
(Herlong, 1994). However microscopic examination shows congestion only (Fig 1E) 
illustrating no remarkable changes in the hepatic tissue of these animals (Feroz et al., 2011a). 
 
Parameters/ 
Groups 
γ-GT 
(µ/l) 
ALP 
(µ/l) 
ALT 
(µ/l) 
TBR 
(mg/dl) 
DBR 
(mg/dl) 
Control 11.28+1.21 55.51+5.92 83.16+5.21 0.32+0.03 0.15+0.01 
Amiodarone 19.41+1.43** 88.34+5.64** 96.60+1.52* 0.30+0.02 0.32+0.05** 
Glibenclamide 11.02+0.75 62.82+2.06 68.50+4.72 0.23+0.03 0.20+0.02 
Los. Pot 8.82+0.80 79.0+3.25** 81.40+7.98 0.21+0.05 0.14+0.02 
Oxcarbazepine 14.46+1.41 53.47+1.26 79.26+2.11 0.25+0.01 0.17+0.02 
Verapamil 10.77+1.37 80.44+6.89** 80.07+3.67 0.53+0.12* 0.13+0.01 
Captopril 13.58+0.55 57.37+2.10 73.94+3.31 0.32+0.06 0.15+0.01 
AGLO 11.21+1.20 79.21+5.11** 76.55+4.16 0.13+0.01* 0.18+0.03 
AGVO 16.78+0.95** 66.62+7.77 70.76+4.25 0.13+0.03* 0.21+0.04 
AGCO 11.95+1.48 47.75+4.03 56.74+4.69** 0.14+0.04* 0.21+0.04 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 1A.Comparison of hepatic parameters following 60 days administration of individual 
drugs and their combinations {Adopted from Feroz et al., 2011(a)}. 
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Parameters/ 
Groups 
γ-GT 
(µ/l) 
ALP 
(µ/l) 
ALT 
(µ/l) 
TBR 
(mg/dl) 
DBR 
(mg/dl) 
Control 11.30+1.21 55.30+5.90 82.70+5.20 0.31+0.03 0.15+0.01 
Amiodarone 19.16+1.42** 88.0+5.70** 96.56+1.50* 0.26+0.02 0.30+0.04** 
Glibenclamide 10.58+0.82 62.42+2.10 67.80+4.80 0.22+0.03 0.16+0.01 
Los. Pot 8.51+ 0.78 79.63+3.10** 80.80+8.0 0.17+0.05 0.13+0.02 
Oxcarbazepine 14.17+1.40 53.96+1.30 78.72+2.11 0.23+0.01 0.16+0.01 
Verapamil 10.39+1.30 81.0+6.80** 79.4+3.60 0.50+0.12* 0.12+0.01 
Captopril 13.17+0.51 56.93+2.20 73.39+3.30 0.30+0.06 0.14+0.01 
AGLO 10.79+1.10 79.0+5.10** 76.10+4.20 0.12+0.01* 0.17+0.03 
AGVO 16.42+0.92** 66.0+7.70 70.51+4.22 0.11+0.02* 0.18+0.03 
AGCO 11.43+1.50 46.90+4.0 54.0+5.10** 0.13+0.04* 0.18+0.03 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
 **p <0.005 highly significant with respect to control 
Table 1B. Comparison of hepatic parameters following drug-free interval of 15 days of 
individual drugs and their combinations {Adopted from Feroz et al., 2011(a)}. 
 
 
 
 
Fig. 1A. Hepatic tissue showing no microscopic change {Adopted from Feroz et al., 2011(a)}. 
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Fig. 1B. Hepatic tissue showing cellular swelling {Adopted from Feroz et al., 2011(a)}. 
 
Fig. 1C. Hepatic tissue showing moderate portal inflammation {Adopted from Feroz et al., 
2011(a)}. 
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Fig. 1D. Hepatic tissue showing congestion and mild mononuclear inflammatory infiltrate 
{Adopted from Feroz et al., 2011(a)}. 
 
Fig. 1E. Hepatic tissue showing congestion {Adopted from Feroz et al., 2011(a)}. 
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3. Biochemical testing and histopathological examination of renal toxicities 
Drugs are a frequent cause of acute kidney injury particularly in patients older than 60 years 
and have a higher occurrence of diabetes and CVD (Naughton, 2008). Renal function test are 
important in assessing the amount and severity of renal damage.  
Table 2A and 2B reveals the comparison of urea and creatinine levels between control 
animals and animals kept on individual drugs and their combinations for a period of 60 
days and then after drug free interval of 15 days in normal therapeutic doses. The 
administration of amiodarone in animals causes increase in the levels of urea and creatinine, 
whereas animals received verapamil showed significant increase in the level of urea only. 
However biochemical changes do not correlate to histopathological changes in renal tissue 
(Fig 2A) hence it is not an indication of renal damage (Feroz et al., 2010). Animals received 
glibenclamide showed no significant changes at biochemical level; however microscopic 
examination of renal tissue reveals mild tubulointerestial nephritis (Fig 2B), which together 
with insignificant rise in serum urea might be an indicative of developing renal damage. 
Significant elevation in serum urea level in animals received amiodarone and verapamil 
alone after drug free interval might be due to slow excretion rate of amiodarone and 
verapamil from the body.  
Animals received AGVO combination showed highly significant rise in urea level though it 
was reversed after the drug-free interval, while animals kept on AGCO combination 
showed highly significant elevation of serum urea and creatinine. Increased creatinine level 
suggests decreased creatinine clearance which is a reliable indicator of decreased glomerular 
filtration rate due to renal damage. However after dug-free interval urea level remained 
highly significant while creatinine level was changed from highly significant to significant 
(Feroz et al., 2010). 
 
Parameters/ 
Groups
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 52.12+4.37 0.64+0.02 
Amiodarone 169.65+5.73** 1.12+0.07** 
Glibenclamide 52.80+2.61 0.70+0.05 
Los. Pot 55.05+1.50 0.64+0.02 
Oxcarbazepine 49.27+1.40 0.58+0.07 
Verapamil 68.14+1.62* 0.71+0.02 
Captopril 62.0+1.83 0.60+0.02 
AGLO 55.28+2.44 0.64+0.07 
AGVO 74.86+6.57** 0.71+0.05 
AGCO 148.54+6.81** 1.20+0.05** 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
 
Table 2A. Comparison of renal parameters following 60 days administration of individual 
drugs and their combinations (Adopted from Feroz et al., 2010). 
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Parameters/ 
Groups 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
 
Control 51.97+4.37 0.63+0.02 
Amiodarone 68.15+1.30* 0.70+0.03 
Glibenclamide 52.40+2.59 0.66+0.03 
Los. Pot 54.61+1.41 0.73+0.05 
Oxcarbazepine 49.0+1.41 0.54+0.03 
Verapamil 61.88+1.46* 0.64+0.03 
Captopril 60.77+1.57 0.67+0.02 
AGLO 54.66+2.45 0.68+0.07 
AGVO 59.20+4.48 0.63+0.05 
AGCO 120.65+6.42** 0.75+0.03* 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 2B. Comparison of renal parameters following drug-free interval of 15 days of 
individual drugs and their combinations (Adopted from Feroz et al., 2010). 
 
 
 
 
Fig. 2A. Renal tissue showing no microscopic change (Adopted from Feroz et al., 2010). 
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Fig. 2B. Renal tissue showing mild tubulointerestial nephritis (Adopted from Feroz et al., 
2010). 
4. Biochemical testing and histopathological examination of cardiac 
toxicities 
Cardiac enzymes are proteins that escape out of injured myocardial cells resulting in 
elevated levels in blood. Table 3A and 3B reveals the comparison of creatinine kinase (CK) 
and aspartate transaminases (AST) levels between control animals and animals kept on 
individual drugs and their combinations for a period of 60 days and then after drug free 
interval of 15 days in normal therapeutic doses. Animals received amiodarone, losartan 
potassium, oxcarbazepine and captopril alone revealed highly significant elevation in the 
level of CK  but these changes do not correlate with histological changes (Fig 3A) (Feroz et 
al., 2010). However animals kept on oxcarbazepine alone revealed significant elevation in 
CK level even after drug free interval which might be an indication of developing 
neuroleptic malignant syndrome (Pelonero et al., 1998). 
The administration of AGLO combination in animals causes significant elevation in CK and 
AST levels, moreover inflammatory changes in the cardiac tissues (Fig 3B) suggest possible 
cardiac injury (Feroz et al., 2010).  There are studies which suggest that raise in CK level 
increases the risk of myocardial infarction (Smith et al., 1976; Kumar et al., 2003; Watanabe 
et al., 2009). Thus simultaneous elevation of AST along with CK and histological changes 
might be indicative of severe myocardial cellular damage (Kratz et al., 2002). There was 
significant decrease in CK level in animal received AGCO combination at the end of dosing 
and after drug-free interval which may be due to reduced muscle mass, wasting or cachexia 
(Feroz et al., 2010). 
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Parameters/ 
Groups 
CK 
(µ/l) 
AST 
(µ/l) 
Control 311.35+12.57 54.07+1.03 
Amiodarone 567.42+29.61** 54.81+2.37 
Glibenclamide 321.26+13.48 48.63+4.69 
Los. Pot 400.84+4.24** 51.36+0.99 
Oxcarbazepine 392.61+14.86** 56.05+1.99 
Verapamil 307.28+6.49 49.42+3.01 
Captopril 590.12+12.59** 57.13+0.80 
AGLO 393.91+21.54** 60.66+1.93* 
AGVO 330.11+38.41 53.05+1.48 
AGCO 275.40+7.30* 50.87+1.29 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
 
Table 3A. Comparison of cardiac parameters following 60 days administration of individual 
drugs and their combinations (Adopted from Feroz et al., 2010). 
 
 
Parameters/ 
Groups
CK 
(µ/l) 
AST 
(µ/l) 
Control 311.01+12.59 53.78+1.02 
Amiodarone 304.16+9.45 54.63+2.32 
Glibenclamide 319.67+12.81 53.24+5.45 
Los. Pot 310.81+3.57 51.33+0.94 
Oxcarbazepine 354.12+15.38* 56.03+1.93 
Verapamil 305.35+6.63 49.28+2.96 
Captopril 346.63+17.37 56.42+0.73 
AGLO 270.56+13.33* 56.57+0.88 
AGVO 307.34+23.83 53.36+1.65 
AGCO 271.31+6.70* 50.75+1.29 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
 
Table 3B. Comparison of cardiac parameters following drug-free interval of 15 days of 
individual drugs and their combinations (Adopted from Feroz et al., 2010). 
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Fig. 3A. Cardiac tissue showing no microscopic change (Adopted from Feroz et al., 2010). 
 
Fig. 3B. Cardiac tissue showing focal pericardial inflammation (Adopted from Feroz et al., 
2010). 
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5. Biochemical testing of lipid profile 
Cholesterol and triglycerides are the most important plasma lipids, crucial for formation of 
cell membrane, synthesis of hormones and offer a source of free fatty acids (Dietschy, 1998). 
Table 4A and 4B reveals the comparison of cholesterol, triglyceride, HDL-C (high density 
lipoprotein cholesterol) and LDL-C (low density lipoprotein cholesterol) levels between 
control animals and animals kept on individual drugs and their combinations for a period of 
60 days and then after drug free interval of 15 days in normal therapeutic doses. The 
administration of losartan potassium and captopril in animals showed highly significant 
decrease in the level of triglyceride, whereas animals kept on AGLO and AGCO 
combinations showed highly significant increase in cholesterol at the end of dosing which 
remained significant even after drug-free interval. There was also highly significant increase 
in LDL-C level in animals kept on AGLO and AGCO combinations which remained 
significant even after drug-free interval (Feroz et al., 2011b). Elevated levels of cholesterol 
and LDL-C are undoubtedly associated with enhanced threat of coronary heart disease 
(Brown, 1984) and cerebrovascular morbidity and mortality. There has been a correlation 
among increased LDL-C and atherosclerosis. Since LDL-C gets deposited in the walls of the 
blood vessel forming atherosclerotic plaque. There are studies which recommend that 
pathological process could be inverted by dropping the serum LDL-C level (Ross, 1993). 
There was also significant increase in HDL-C in animals kept on oxcarbazepine alone and 
AGCO in combination at the end of dosing and following drug-free interval; however 
reason of elevated HDL-C is yet to be explored (Feroz et al., 2011b). 
 
 
 
Parameters/ 
Groups 
Cholesterol 
(mg/dl) 
Triglyceride 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
Control 91.84+2.65 102.65+2.45 3.10+0.13 28.15+1.90 
Amiodarone 88.80+0.62 100.51+2.97 3.07+0.04 27.04+1.13 
Glibenclamide 93.37+3.07 106.77+4.71 3.28+0.06 23.25+2.08 
Los. Pot 92.77+0.57 91.94+2.86* 3.15+0.07 34.87+1.70 
Oxcarbazepine 95.08+1.26 97.08+1.45 3.37+0.05* 29.38+2.03 
Verapamil 96.90+1.13 108.53+3.32 3.31+0.08 25.24+1.95 
Captopril 96.06+2.89 93.40+4.47* 3.32+0.07 34.18+2.26 
AGLO 105.15+3.94** 100.20+2.90 2.93+0.05 46.35+3.50** 
AGVO 95.93+1.21 104.46+1.31 3.27+0.04 27.41+1.80 
AGCO 173.53+4.22** 95.35+3.17 3.40+0.08** 108.83+6.13** 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
 
 
 
Table 4A. Comparison of lipid profile following 60 days administration of individual drugs 
and their combinations {Adopted from Feroz et al., 2011(b)}. 
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Parameters/ 
Groups 
Cholesterol 
(mg/dl) 
Triglyceride 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
Control 91.61+2.52 102.12+2.46 2.98+0.12 30.56+1.68 
Amiodarone 88.18+0.75 100.26+2.93 2.96+0.04 28.81+1.25 
Glibenclamide 93.80+3.10 106.7+4.59 3.16+0.05 26.38+2.06 
Los. Pot 92.66+0.65 95.72+1.94 3.04+0.06 34.43+1.22 
Oxcarbazepine 94.82+1.33 96.91+1.52 3.26+0.05** 31.38+1.96 
Verapamil 96.01+1.27 104.27+1.81 3.18+0.07 29.60+1.90 
Captopril 95.37+2.87 95.64+3.69 3.21+0.07 36.05+1.65 
AGLO 104.31+3.91** 97.97+2.48 2.83+0.05 48.71+3.31** 
AGVO 94.98+1.33 102.40+2.11 3.13+0.04 30.85+1.62 
AGCO 99.73+1.18* 94.72+3.13 3.26+0.05** 37.88+2.70** 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
 
 
Table 4B. Comparison of lipid profile following drug-free interval of 15 days of individual 
drugs and their combinations {Adopted from Feroz et al., 2011(b)}. 
6. Biochemical testing of glucose 
Table 5A and 5B reveals the comparison of glucose level between control animals and 
animals kept on individual drugs and their combinations for a period of 60 days and then 
after drug free interval of 15 days in normal therapeutic doses. AGCO combination showed 
significant increase in glucose level in rabbits at the completion of dosing period of 60 days 
and following drug-free interval (Feroz et al., 2011b). Elevated blood glucose level may be 
due to elevation in the level of cholesterol and LDL-C, because diabetes mellitus is a group 
of heterogenous, autoimmune, hormonal and metabolic disorders, frequently occurs along 
with hypertension, hyperlipidemia and obesity (Mahomed and Ojewole, 2003), which also 
augmented the possibility of coronary heart disease (Howard et al., 2000), however threat of 
CVD fatality in diabetic persons may be as high as that in non-diabetic persons with prior 
myocardial infarction (Haffner et al., 1998). There was also a significant elevation in glucose 
level in animals kept on captopril and oxcarbazepine alone, however it has to be elucidated. 
Conversely animal kept on glibenclamide alone revealed highly significant decrease in 
glucose level because the major mechanism of action of glibenclamide is the stimulation of 
insulin release and the inhibition of glucagon secretion; conversely it was inverted following 
drug-free interval (Feroz et al., 2011b). 
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Parameter/ Groups 
Glucose 
(mg/dl) 
Control 122.20+7.60 
Amiodarone 111.84+3.30 
Glibenclamide 75.20+5.79** 
Los. Pot 119.67+4.0 
Oxcarbazepine 142.17+4.54** 
Verapamil 123.33+2.31 
Captopril 146.06+4.72** 
AGLO 102.50+6.12 
AGVO 111.88+3.11 
AGCO 145.44+2.93** 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 5A. Comparison of glucose following 60 days administration of individual drugs and 
their combinations {Adopted from Feroz et al., 2011(b)} 
 
Parameter/ Groups 
Glucose 
(mg/dl) 
Control 123.40+7.40 
Amiodarone 113.76+3.10 
Glibenclamide 104.50+5.40 
Los. Pot 122.30+4.30 
Oxcarbazepine 141.50+4.70 
Verapamil 124.39+2.30 
Captopril 144.30+4.30* 
AGLO 102.60+6.10 
AGVO 112.11+3.10 
AGCO 137.90+3.60* 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 5B. Comparison of glucose following drug-free interval of 15 days of individual drugs 
and their combinations {Adopted from Feroz et al., 2011(b)}. 
7. Biochemical testing of electrolytes  
Table 6A and 6B reveals the comparison of sodium, potassium and calcium concentrations 
between control animals and animals kept on individual drugs and their combinations for a 
period of 60 days and then after drug free interval of 15 days in normal therapeutic doses. 
The balance of electrolytes in our bodies is essential for normal cellular function, since it 
promotes fluid balance, maintain blood volume, facilitate fluid absorption and generate 
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impulses. Significant alterations may occur in electrolytes following multiple drug 
administration. There has been significant decrease in concentration of sodium in animals 
received amiodarone (Feroz et al., 2009), which has potential for significant morbidity and 
mortality (Goh, 2004). However this decrease became insignificant following drug-free 
interval. Similarly there was highly significant decrease in serum calcium in animal received 
glibenclamide, losartan potassium, verapamil, oxcarbazepine, captopril and combination of 
these drugs (Feroz et al., 2009). Calcium is essentially required for development and 
maintenance of bones, not only regulate nerve function, but also contributes to the 
contraction of the muscles and heart. There are studies which suggest that amiodarone 
induces vitamin D deficiency in individuals not exposed to sunlight (Campbell and Allain, 
2006). Vitamin D is essentially required for absorption of calcium; hence in the study by 
Feroz et al 2009 hypocalcaemia in animals on amiodarone alone or in combination might be 
due to the deficiency of vitamin D (Cooper and Gittoes, 2008). However reason for 
hypocalcaemia in other animal groups is yet to be explored. There was highly significant 
increase in calcium after drug free interval in animals received AGVO combination, this 
increase in calcium might be due to increase bone resorption, or gastrointestinal absorption 
or decreased elimination by the kidneys (Strewler, 2000). Hypercalcemia is always a 
concern, because elevated concentrations can result in renal failure, mineralization of the 
other soft tissues, cardiac arrhythmia and dysfunction (Sakals et al., 2006). Animals received 
AGCO combination also showed decrease in potassium level at the end of dosing as well as 
following drug-free interval. A decreased serum potassium concentration points to 
disturbance in normal homeostasis which might be an indication of muscle necrosis. 
However potassium level in animals received AGVO combination was significantly increase 
after drug-free interval. Hyperkalemia because of drugs most frequently occurs from 
impaired renal potassium excretion. On the other hand, disturbed cellular uptake of a 
potassium load as well as unnecessary intake or infusion of potassium-containing 
substances may also induce hyperkalemia. Therefore prescribing physicians must be 
conscious about medications that can precipitate hyperkalemia (Perazella, 2000). 
 
Parameters/ 
Groups 
Sodium 
(µg/ml) 
Potassium 
(µg/ml) 
Calcium 
(µg/ml) 
Control 178.50+5.40 5.96+0.38 16.80+1.30 
Amiodarone 156.16+3.40* 5.46+0.66 11.34+0.23** 
Glibenclamide 187.80+8.90 6.44+0.61 11.04+0.91** 
Los. Pot 171.92+2.80 5.36+0.34 11.70+0.33** 
Oxcarbazepine 182.70+6.10 5.40+0.24 10.58+0.33** 
Verapamil 181.80+9.40 6.04+0.43 11.72+0.52** 
Captopril 182.40 11.0 5.50+0.37 10.78+0.52** 
AGLO 185.60+11.0 5.26+0.14 10.30+0.51** 
AGVO 184.40+5.90 5.66+0.30 12.50+0.59** 
AGCO 173.30+7.0 4.54+0.32* 8.92+0.80** 
n=5 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 6A. Comparison of sodium, potassium and calcium following 60 days administration 
of individual drugs and their combinations (Adopted from Feroz et al., 2009). 
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Parameters/ 
Groups 
Sodium 
(µg/ml) 
Potassium 
(µg/ml) 
Calcium 
(µg/ml) 
Control 178.70+5.80 5.90+0.37 16.80+1.25 
Amiodarone 162.72+2.30 5.40+0.65 15.70+1.20 
Glibenclamide 181.46+2.90 6.38+0.59 17.04+0.91 
Los. Pot 172.50+2.80 5.28+0.31 17.70+0.33 
Oxcarbazepine 182.90+6.0 5.26+0.24 16.58+0.33 
Verapamil 181.40+9.40 6.0+0.44 17.72+0.52 
Captopril 180.60+10.0 5.48+0.33 16.72+0.49 
AGLO 175.70+7.40 5.22+0.10 16.30+0.49 
AGVO 175.56+3.10 7.0+0.07* 20.38+0.28** 
AGCO 170.40+5.90 3.94+0.15** 13.16+0.87** 
n=5 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control  
Table 6B. Comparison of sodium, potassium and calcium following drug-free interval of 15 
days of individual drugs and their combinations (Adopted from Feroz et al., 2009). 
8. Hematological testing 
Table 7A and 7B reveals the comparison of hemoglobin concentration, platelet, leucocytes 
and erythrocytes count between control animals and animals kept on individual drugs and 
their combinations for a period of 60 days and then after drug free interval of 15 days in 
normal therapeutic doses. Changes in hematological parameters such as erythrocytes, 
leucocytes and platelet count and hemoglobin had always a serious concern following 
administration of drugs individually as well as in combination. There has been significant 
increase in platelet count in animal group received captopril and oxcarbazepine alone (Feroz 
et al., 2011a). Increased in platelet might be due to inflammatory disorder or iron deficiency 
anemia (Schafer, 2004), however there was also a significant increase in leucocytes count in 
animal group kept on oxcarbazepine alone, on the other hand animal group received 
amiodarone alone showed significant decrease in leucocytes count which might be due to 
disturbance in immune system, where as platelet count was not changed significantly, 
though amiodarone is known to produce thrombocytopenia (Weinberger et al., 1987). 
Study conducted by Feroz et al 2011a revealed more severe hematological changes in 
animals received drugs in combination throughout the experimental period in comparison 
to animals received the drugs individually. Concurrent administration of AGLO 
combination showed a significant increased in leucocytes count which might be an indicator 
of an infection, inflammation, or allergy. On the other hand concurrent administration of 
AGVO combination showed highly significant increase in erythrocytes count while the 
other hematological parameters were not altered significantly.   
There was significant increase and decrease in leucocytes and platelet count respectively in 
animals kept on AGCO combination. Decrease in platelet count may be due to insufficient 
production of platelet in bone marrow, a variety of reasons such as leukemia, lymphomas 
and several bone marrow disorders may have this effect on platelet count (McMillan, 2007). 
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Spleen enlargement may also decrease platelet count, or it may probably due to folic acid 
deficiency (Mant et al., 1979). 
 
Parameters/ 
Groups 
Hemoglobin 
(mg/dl) 
Platelet 
(x105/c.mm) 
Leucocytes 
(x103/c.mm) 
Erythrocytes 
(x106/c.mm) 
Control 10.62+0.23 412+39 6.26+0.35 6.14+0.16 
Amiodarone 11.04+0.37 539+56 3.73+0.44* 6.12+0.26 
Glibenclamide 9.90+0.28 433+62 5.61+0.57 5.83+0.19 
Los. Pot 10.53+0.72 417+40 5.10+0.69 6.05+0.44 
Oxcarbazepine 12.33+1.03 561+50* 8.99+0.78* 6.91+0.67 
Verapamil 9.13+0.62 396+48 5.47+0.55 5.25+0.31 
Captopril 10.06+0.66 559+66* 4.97+0.63 5.66+0.49 
AGLO 10.54+0.69 310+17 8.43+1.24* 5.38+0.23 
AGVO 12.01+0.93 320+35 7.74+0.88 9.65+1.22** 
AGCO 9.91+0.53 279+16* 8.75+1.01* 6.23+0.36 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 7A. Comparison of hematological parameters following 60 days administration of 
individual drugs and their combinations {Adopted from Feroz et al., 2011(a)}. 
 
Parameters/ 
Groups 
Hemoglobin 
(mg/dl) 
Platelet 
(x105/c.mm) 
Leucocytes 
(x103/c.mm) 
Erythrocytes 
(x106/c.mm) 
Control 10.58+0.24 416+40 6.26+0.36 6.03+0.20 
Amiodarone 10.84+0.33 541+55 3.66+0.45* 6.18+0.27 
Glibenclamide 9.86+0.25 445+57 5.47+0.59 5.85+0.20 
Los. Pot 10.44+0.76 429+37 5.01+0.69 6.09+0.45 
Oxcarbazepine 12.23+1.10 549+43* 8.90+0.77* 6.98+0.66 
Verapamil 9.03+0.59 385+46 5.43+0.56 5.24+0.31 
Captopril 10.02+0.64 558+66* 4.93+0.63 5.66+0.49 
AGLO 10.42+0.72 324+21 8.40+1.22* 5.38+0.24 
AGVO 12.03+0.87 317+34 7.63+0.87 9.65+1.22* 
AGCO 9.73+0.54 281+16* 8.62+0.99* 6.27+0.37 
n=9 
Mean + S.E.M 
*p < 0.05 significant with respect to control 
**p <0.005 highly significant with respect to control 
Table 7B. Comparison of hematological parameters following drug-free interval of 15 days 
of individual drugs and their combinations {Adopted from Feroz et al., 2011(a)}. 
9. Conclusion 
The problems associated with drug therapy are a significant challenge to health care 
providers, especially in developing countries where health care system is poor. Minimizing 
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the risk for drug interactions is the desirable aim in drug therapy, since interactions can 
leads to significant morbidity, mortality and patient quality of life. Individuals taking 
multiple medications are at increased threat of adverse drug reactions; hence when ever 
multiple drugs are to be administered in case of multiple disorders such as epilepsy, 
hypertension, diabetes mellitus and arrhythmias drug treatment should be monitored to 
avoid adverse effects of the drugs. Studies conducted by Feroz et al not only provides 
valuable information pertaining to gross toxicities, microscopic changes and toxic effects on 
hepatic, renal, cardiac, lipid profile, glucose, electrolytes and hematological parameters but 
also give clues about the drug combination having higher incidence of cumulative toxicities. 
These studies in general has revealed that animals received AGCO combination 
comparatively showed higher toxicities with marked decrease in ALT, TBR, CK, potassium, 
calcium and platelet count and increase in urea, creatinine, cholesterol, LDL-C, glucose and 
leucocytes count. However further studies on more animals and human beings are 
necessary to defend the utilization of multiple drugs. 
These studies provides detailed evaluation of dug interaction and adverse effect of 
cumulative drug therapy; such observations are of undisputed importance but it should not 
be disregarded that pathway of drug metabolism in man may be quite dissimilar from that 
which has been determined in many species of laboratory animal, hence trial in man is the 
only valid way of establish drug interactions, before reaching to any final conclusion. 
However the risk of adverse drug reactions and drug interactions can be reduced by 
forming drug information centers, continuous medical education and incorporation of 
adverse drug reaction reporting into the clinical activities of the physicians (Oshikoya and 
Awobusuyi, 2009).  
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